Biohaven (BHVN) Stock Plummets After Pausing Midstage Seizure Treatment Study Due to Safety Concerns and FDA Toxicity Assessment Requirement
Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment opakalim due to safety concerns. The Food and Drug Administration (FDA) is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, which is in testing for focal onset seizures, after issues were observed in rats.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
NVS Coin: Project Status, Trading Channels, and High-Risk Warning
-
2
What is Fantom (FTM)? FTM Token Analysis and Future Outlook
-
3
BMP Token Analysis: Cryptocurrency with Multiple Identities and Investment Considerations
-
4
What is ELCASH Coin? Electric Cash Token Analysis and Trading Channels
-
5
Key Differences Between US and A-Share Markets: A Five-Core Mechanism Analysis
-
6
NUKE Coin: A Multifaceted Analysis of Homonymous Tokens in the Robinhood Ecosystem, Gaming, and Payment Solutions
-
7
FER Token: A Guide to Trading and Acquiring Ferro Protocol's Native Token
-
8
Filecoin (FIL) Price Potential Analysis: Influencing Factors and Market Outlook
-
9
Trump Coin (TRUMP) Future Trend Analysis: Influencing Factors and Market Outlook
-
10
WAHED Coin Analysis: Project Vision, Technology, and Trading Status
Markets Today
Recommended Reading












